Thermally stable trimetrexates and processes for producing the same
CA 2333274 A1 · Owner: Stogniew, Martin · Inventors: Stogniew, Martin; Grafe, Ingomar; Morsdorf, Johann
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides for thermally stable forms of 2,4-diamino-5methyl-6-(3,4,5-trimethoxyanilino)methyl quinazoline or trimetrexate. A , crystalline 2,4-diamino-5-methyl-6-(3,4,5-trimethoxyanilino)methyl quinazoline monohydrate, or trimetrexate monohydrate belonging to the space , group P<o>1</o>(#2) and having a triclinic cell with dimensions of about a = 7.699 .ANG. b = 9.606 .ANG. and c = 13.012 .ANG. is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-(3,4,5-trimethoxyphenylimino)-methinyl quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds including , crystalline …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 17, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 17, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 17, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.